Loading…
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $96M | $49M | $81M | 22.6% | 17.9% | - |
| 2024 | $1.2B | $-43M | $-87M | $42M | -58.2% | 17.4% | -465.2% |
| 2023 | $1.0B | $59M | $24M | $56M | 39.9% | 15.1% | -32.5% |
| 2022 | $909M | $68M | $35M | $32M | 46.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 908.91 | 1,046.19 | 1,228.41 | 1,448.68 |
| Cost Of Revenue | 723.04 | 837.88 | 984.04 | 1,155.97 |
| Gross Profit | 185.87 | 208.31 | 244.37 | 292.72 |
| Operating Expense | 133.88 | 167.36 | 307.29 | 220.02 |
| Operating Income | 51.99 | 40.95 | -62.92 | 72.70 |
| EBITDA | 68.15 | 58.81 | -43.43 | 96.42 |
| EBIT | 51.59 | 40.58 | -63.20 | 74.09 |
| Pretax Income | 49.66 | 37.72 | -66.48 | 73.42 |
| Tax Provision | 0 | 0 | 4.56 | 24.46 |
| Net Income | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income Common Stockholders | 35.42 | 0 | -110.05 | 49.22 |
| Total Expenses | 856.92 | 1,005.25 | 1,291.33 | 1,375.98 |
| Interest Expense | 1.93 | 2.86 | 3.28 | 0.67 |
| Selling General And Administration | 133.88 | 167.36 | 307.29 | 220.02 |
| Normalized EBITDA | 68.15 | 58.81 | -43.43 | 96.42 |
| Normalized Income | 35.42 | 23.90 | -87.29 | 49.22 |
| Basic EPS | 0.58 | 0 | -1.77 | 0 |
| Diluted EPS | 0.58 | 0 | -1.77 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0 | 0.21 | 0.33 |
| Net Income From Continuing Operation Net Minority Interest | 35.42 | 23.90 | -87.29 | 49.22 |
| Reconciled Depreciation | 16.56 | 18.23 | 19.77 | 22.34 |
| Reconciled Cost Of Revenue | 723.04 | 837.88 | 984.04 | 1,155.97 |
| Net Interest Income | -1.93 | -2.86 | -3.28 | -0.67 |
| Net Income From Continuing And Discontinued Operation | 35.42 | 23.90 | -87.29 | 49.22 |
| Total Operating Income As Reported | 51.99 | 40.95 | -62.92 | 72.70 |
| Diluted Average Shares | 60.84 | 60.84 | 62.01 | 0 |
| Basic Average Shares | 60.84 | 60.84 | 62.01 | 0 |
| Diluted NI Availto Com Stockholders | 35.42 | 0 | -110.05 | 49.22 |
| Otherunder Preferred Stock Dividend | 0 | 23.90 | 22.76 | 0 |
| Minority Interests | -14.24 | -13.82 | -16.25 | 0.26 |
| Net Income Including Noncontrolling Interests | 49.66 | 37.72 | -71.03 | 48.96 |
| Net Income Continuous Operations | 49.66 | 37.72 | -71.03 | 48.96 |
| Other Income Expense | -0.40 | -0.37 | -0.28 | 1.39 |
| Other Non Operating Income Expenses | -0.40 | -0.37 | -0.28 | 1.39 |
| Net Non Operating Interest Income Expense | -1.93 | -2.86 | -3.28 | -0.67 |
| Interest Expense Non Operating | 1.93 | 2.86 | 3.28 | 0.67 |
| Other Operating Expenses | -3.38 | 0 | 0 | 0 |
| Selling And Marketing Expense | 137.26 | 0 | 0 | 0 |
| General And Administrative Expense | 0 | 0 | 0 | 0 |
| Salaries And Wages | 0 | 0 | 0 | 0 |
| Operating Revenue | 908.91 | 1,046.19 | 1,228.41 | 1,448.68 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc.this co. | GRDN | $2.4B | 48.17↑ premium | 11.56 | 22.6% | 23.10 |
| Enliven Therapeutics, Inc. | ELVN | $2.6B | - | 5.48 | -22.6% | -17.36 |
| Vera Therapeutics, Inc. | VERA | $2.6B | - | 4.23 | -49.6% | -6.09 |
| Heartflow, Inc. | HTFL | $2.5B | - | 8.38 | -38.8% | -37.97 |
| Celldex Therapeutics, Inc. | CLDX |
| $2.5B |
| - |
| 4.06 |
| -49.1% |
| -5.72 |
| Disc Medicine, Inc. | IRON | $2.5B | - | 3.38 | -28.7% | -7.48 |
| IDEAYA Biosciences, Inc. | IDYA | $2.5B | - | 2.41 | -11.1% | -11.82 |
| Relay Therapeutics, Inc. | RLAY | $2.4B | - | 3.85 | -48.8% | -5.76 |
| BioCryst Pharmaceuticals, Inc. | BCRX | $2.3B | 7.43 | -16.08 | -221.4% | 7.00 |
| Peer Median | - | 7.43 | 3.96 | -43.8% | -6.79 | |